intravenous lidocaine (IVL) — Competitive Intelligence Brief

intravenous lidocaine (IVL) (intravenous lidocaine (IVL)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic; Class IB antiarrhythmic. Area: Cardiovascular; Anesthesia; Pain management.

marketed Local anesthetic; Class IB antiarrhythmic Voltage-gated sodium channels Cardiovascular; Anesthesia; Pain management Small molecule

Target snapshot

intravenous lidocaine (IVL) (intravenous lidocaine (IVL)) — Ciusss de L'Est de l'Île de Montréal. Intravenous lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravenous lidocaine (IVL) TARGET	intravenous lidocaine (IVL)	Ciusss de L'Est de l'Île de Montréal	marketed	Local anesthetic; Class IB antiarrhythmic	Voltage-gated sodium channels
extraarticular injection with ropivacaine	extraarticular injection with ropivacaine	Hvidovre University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
nortriptyline + topiramate	nortriptyline + topiramate	University of California, Irvine	marketed	Tricyclic antidepressant + anticonvulsant combination	Norepinephrine transporter, serotonin transporter, voltage-gated sodium channels, GABA receptors
Articaine / EPINEPHrine Cartridge	Articaine / EPINEPHrine Cartridge	Universidad de Antioquia	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels (articaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
Lidocaine-Prilocaine Cream 2.5-2.5%	Lidocaine-Prilocaine Cream 2.5-2.5%	Centre Hospitalier le Mans	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine skin wheal	Lidocaine skin wheal	George Washington University	marketed	Local anesthetic	Voltage-gated sodium channels
Lidoderm 5 % Topical Patch	Lidoderm 5 % Topical Patch	Oregon Health and Science University	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic; Class IB antiarrhythmic class)

1. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class